Globalstar vs Personalis Inc. Common Stock — how do they compare? Globalstar trades at $82.43 (market cap $10.68B), while Personalis Inc. Common Stock trades at $15.95 (market cap $1.70B). The key difference: Globalstar is far larger — about 6.3× Personalis Inc. Common Stock's market cap, and Globalstar is trading nearer its 52-week high, Personalis Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Globalstar for 23 Days and Personalis Inc. Common Stock for 0 Days on average.
| GSAT | PSNL | |
|---|---|---|
Market Cap | $10.68B | $1.70B |
Volume | 642,471 | 3,262,398 |
Sector | Media | Health |
52-Week High | $84.43 | $18.38 |
52-Week Low | $41.54 | $5.04 |
Typical Hold Time | 23 Days | 0 Days |
Enterprise Value | $10.68B | $1.52B |
Signals from Pluang's Aura AI — not financial advice
GSAT trades at $82.68, down 0.43% with a bullish technical outlook. The company shows strong gross margins at 62.25% but faces profitability challenges with negative net income margins. Recent satellite launches and infrastructure expansion in Greece signal growth potential, though earnings have consistently missed expectations.
Investment outlook remains mixed with 40% analyst buy ratings but persistent losses. Key risks include execution challenges and high valuation multiples. Positive cash flow and strategic developments provide upside catalysts, but profitability improvement is critical for sustained shareholder value.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Globalstar provides satellite and terrestrial connectivity services, including voice, data, asset tracking, and private wireless solutions. It operates a low-Earth-orbit satellite network and holds licensed mid-band spectrum.
Read more on GSAT →Personalis Inc. is a cancer genomics company that provides tumor- and blood-based DNA and RNA sequencing tests, including its NeXT Personal liquid biopsy test for cancer monitoring.
Read more on PSNL →